-DOCSTART- -X- O
In -X- _ O
the -X- _ O
recent -X- _ O
years -X- _ O
, -X- _ O
it -X- _ O
has -X- _ O
been -X- _ O
demonstrated -X- _ O
that -X- _ O
the -X- _ O
biological -X- _ O
activity -X- _ O
of -X- _ O
mesenchymal -X- _ O
stem -X- _ O
cells -X- _ O
( -X- _ O
MSCs -X- _ O
) -X- _ O
is -X- _ O
mediated -X- _ O
through -X- _ O
the -X- _ O
release -X- _ O
of -X- _ O
paracrine -X- _ O
factors. -X- _ O
Many -X- _ O
of -X- _ O
these -X- _ O
factors -X- _ O
are -X- _ O
released -X- _ O
into -X- _ O
exosomes -X- _ O
, -X- _ O
which -X- _ O
are -X- _ O
small -X- _ O
membranous -X- _ O
vesicles -X- _ O
that -X- _ O
participate -X- _ O
in -X- _ O
cell–cell -X- _ O
communication. -X- _ O
Exosomes -X- _ O
from -X- _ O
MSCs -X- _ O
are -X- _ O
thought -X- _ O
to -X- _ O
have -X- _ O
similar -X- _ O
functions -X- _ O
to -X- _ O
MSCs -X- _ O
such -X- _ O
as -X- _ O
repairing -X- _ O
and -X- _ O
regeneration -X- _ O
of -X- _ O
damaged -X- _ O
tissue -X- _ O
, -X- _ O
but -X- _ O
little -X- _ O
is -X- _ O
known -X- _ O
about -X- _ O
the -X- _ O
immunomodulatory -X- _ O
effect -X- _ O
of -X- _ O
these -X- _ O
vesicles. -X- _ O
Based -X- _ O
on -X- _ O
an -X- _ O
extensive -X- _ O
bibliography -X- _ O
where -X- _ O
the -X- _ O
immunomodulatory -X- _ O
capacity -X- _ O
of -X- _ O
MSCs -X- _ O
has -X- _ O
been -X- _ O
demonstrated -X- _ O
, -X- _ O
here -X- _ O
we -X- _ O
hypothesized -X- _ O
that -X- _ O
released -X- _ O
exosomes -X- _ O
from -X- _ O
MSCs -X- _ O
may -X- _ O
have -X- _ O
an -X- _ O
immunomodulatory -X- _ O
role -X- _ O
on -X- _ O
the -X- _ O
differentiation -X- _ O
, -X- _ O
activation -X- _ O
and -X- _ O
function -X- _ O
of -X- _ O
different -X- _ O
lymphocyte -X- _ O
subsets. -X- _ O
According -X- _ O
to -X- _ O
this -X- _ O
hypothesis -X- _ O
, -X- _ O
in -X- _ O
vitro -X- _ O
experiments -X- _ O
were -X- _ O
performed -X- _ O
to -X- _ O
characterize -X- _ O
the -X- _ O
immunomodulatory -X- _ O
effect -X- _ O
of -X- _ O
human -X- _ B-Patient
adipose -X- _ I-Patient
MSCs -X- _ I-Patient
derived -X- _ O
exosomes -X- _ B-Intervention
( -X- _ I-Intervention
exo-hASCs -X- _ I-Intervention
) -X- _ I-Intervention
on -X- _ O
in -X- _ O
vitro -X- _ O
stimulated -X- _ O
T -X- _ O
cells. -X- _ O
The -X- _ O
phenotypic -X- _ O
characterization -X- _ O
of -X- _ O
cytotoxic -X- _ O
and -X- _ O
helper -X- _ O
T -X- _ O
cells -X- _ O
( -X- _ O
activation -X- _ O
and -X- _ O
differentiation -X- _ O
markers -X- _ O
) -X- _ O
together -X- _ O
with -X- _ O
functional -X- _ O
assays -X- _ O
( -X- _ O
proliferation -X- _ O
and -X- _ O
IFN-γ -X- _ O
production -X- _ O
) -X- _ O
demonstrated -X- _ O
that -X- _ O
exo-hASCs -X- _ O
exerted -X- _ O
an -X- _ O
inhibitory -X- _ B-Outcome
effect -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
differentiation -X- _ I-Outcome
and -X- _ I-Outcome
activation -X- _ I-Outcome
of -X- _ I-Outcome
T -X- _ I-Outcome
cells -X- _ I-Outcome
as -X- _ I-Outcome
well -X- _ I-Outcome
as -X- _ I-Outcome
a -X- _ I-Outcome
reduced -X- _ I-Outcome
T -X- _ I-Outcome
cell -X- _ I-Outcome
proliferation -X- _ I-Outcome
and -X- _ I-Outcome
IFN-γ -X- _ I-Outcome
release -X- _ I-Outcome
on -X- _ I-Outcome
in -X- _ I-Outcome
vitro -X- _ I-Outcome
stimulated -X- _ I-Outcome
cells. -X- _ I-Outcome
In -X- _ O
summary -X- _ O
, -X- _ O
here -X- _ O
we -X- _ O
demonstrate -X- _ O
that -X- _ O
MSCs-derived -X- _ O
exosomes -X- _ O
are -X- _ O
a -X- _ O
cell-derived -X- _ O
product -X- _ O
that -X- _ O
could -X- _ O
be -X- _ O
considered -X- _ O
as -X- _ O
a -X- _ O
therapeutic -X- _ O
agent -X- _ O
for -X- _ O
the -X- _ O
treatment -X- _ O
of -X- _ O
inflammation-related -X- _ O
diseases -X- _ O
. -X- _ O

